Business Context and Reporting Period
Company: NeoGenomics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 17, 2026
Event: Pricing of an offering of convertible senior notes due 2032 to qualified institutional buyers pursuant to Rule 144A.
Key Financial Metrics
This filing is a current report regarding a capital market event and does not contain audited financial statements, revenue, profit, cash flow, margin, or liquidity data. The filing text does not provide a clear value for these operational metrics.
Material Changes
The material change reported is the execution of a new debt financing transaction. The Company has priced an offering of convertible senior notes due 2032. Specific terms such as the principal amount, interest rate, conversion price, or total proceeds are not detailed in the body of this 8-K filing but are referenced in the attached press release (Exhibit 99.1).
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the pricing of the Convertible Notes Offering but includes no forward-looking guidance or management discussion regarding future performance.
Risks and Contingencies: The filing includes a standard disclaimer stating that the report does not constitute an offer to sell or a solicitation of an offer to buy securities in jurisdictions where such offering would be unlawful.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific terms of the convertible senior notes, including principal amount, coupon rate, and conversion ratio.
- Verify the use of proceeds from the Convertible Notes Offering as disclosed in the full press release.
- Check for any subsequent filings (e.g., Prospectus Supplement) that may detail the final terms and conditions of the notes.
- Confirm the impact of this new debt on the Company's existing capital structure and leverage ratios.